Current Issue March 2012, Vol. 36, No. 3

Issue Highlights

Invited Review

What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?
March 2012(Vol. 36 | No. 3 | Pages 253-261)
Michael W. Deininger, Paul Manley

Meeting Report

Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop
March 2012(Vol. 36 | No. 3 | Pages 264-270)
Uwe Platzbecker, Valeria Santini, Ghulam J. Mufti, Claudia Haferlach, Jaroslaw P. Maciejewski, Sophie Park, Francesc Solé, Arjan A. van de Loosdrecht, Detlef Haase

Clinical Studies

Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model
March 2012(Vol. 36 | No. 3 | Pages 271-274)
Beate Schultheis, Bart A. Nijmeijer, H. Yin, Roger G. Gosden, Junia V. Melo

Neutropenia at baseline could indicate poor prognosis in low/intermediate risk myelodysplastic syndrome patients
10 February 2012
Massimo Breccia, Giuseppina Loglisci, Adriano Salaroli, Paola Finsinger, Alessandra Serrao, Luigi Petrucci, Giuliana Alimena
We read with interest the article by Cordoba et al. , which reported that the degree of neutropenia at baseline has a prognostic impact in low risk myelodysplastic syndromes (MDS). They referred that ...
A novel three-way variant t(4;17;5)(p16;q23;q31) in a case of secondary plasma cell leukemia
10 February 2012
Yoonjung Kim, Juwon Kim, Seo-Jin Park, Jong Rak Choi, Kyung-A Lee, Yu Ri Kim
Plasma cell leukemia (PCL) is a rare and aggressive variant of plasma cell myeloma that is classically divided into primary and secondary subtypes. The incidence of sPCL (40% of all PCL cases) which ...
AZA-ESA combo: A new standard for higher risk MDS?
10 February 2012
Moshe Mittelman
The cloning of the erythropoietin (EPO) gene, more than two decades ago , followed by the production of recombinant human erythropoietin (rHuEPO), allowed millions of patients with anemia to benefit f...
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
10 February 2012
Gail J. Roboz, Usama Wissa, Ellen K. Ritchie, Usama Gergis, Sebastian Mayer, Joseph M. Scandura, Paul J. Christos, Eric J. Feldman
Abstract: This study compares outcomes of low-intensity versus standard-intensity induction strategies for older patients with acute myeloid leukemia at the Weill Cornell Leukemia Program. From 1999 t...
Sequential array comparative genomic hybridization analysis identifies copy number changes during blastic transformation of chronic myeloid leukemia
10 February 2012
Seung-Tae Lee, Yongick Ji, Hee-Jin Kim, Chang-Seok Ki, Chul Won Jung, Jong-Won Kim, Sun-Hee Kim
Abstract: The present study was performed to provide direct evidence on copy number changes during progression from chronic phase (CP) to blastic phase (BP) in chronic myeloid leukemia (CML) through a...

View More Articles in Press...

Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia
August 2011 (Vol. 35 | No. 8 | Pages 1060-1065)
Wei Xu, Yin-Hua Wang, Lei Fan, Cheng Fang, Dan-Xia Zhu, Dong-Mei Wang, Chun Qiao, Yu-Jie Wu, Jian-Yong Li
Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia?
January 2011 (Vol. 35 | No. 1 | Pages e11-e12)
Shun-ichi Kimura, Shinichi Kako, Hidenori Wada, Kana Sakamoto, Masahiro Ashizawa, Miki Sato, Kiriko Terasako, Misato Kikuchi, Hideki Nakasone, Shinya Okuda, Rie Yamazaki, Kumi Oshima, Junji Nishida, Takuro Watanabe, Yoshinobu Kanda
- Full Text
- PDF (95 KB)
Alloreactive natural killer cells in hematopoietic stem cell transplantation
January 2011 (Vol. 35 | No. 1 | Pages 14-21)
Hollie J. Pegram, David S. Ritchie, Mark J. Smyth, Andres Wiernik, H. Miles Prince, Phillip K. Darcy, Michael H. Kershaw
Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases
July 2011 (Vol. 35 | No. 7 | Pages 863-867)
Thorsten Braun, Stéphane de Botton, Anne-Laure Taksin, Sophie Park, Odile Beyne-Rauzy, Valérie Coiteux, Rosa Sapena, Anne Lazareth, Geneviève Leroux, Khaled Guenda, Bruno Cassinat, Michaela Fontenay, Norbert Vey, Agnès Guerci, François Dreyfus, Dominique Bordessoule, Aspasia Stamatoullas, Sylvie Castaigne, Christine Terré, Virginie Eclache, Pierre Fenaux, Lionel Adès
MPN-associated myelofibrosis (MPN-MF)
January 2011 (Vol. 35 | No. 1 | Pages 12-13)
R.A. Mesa, A. Green, G. Barosi, S. Verstovsek, J. Vardiman, R.P. Gale
- Full Text
- PDF (155 KB)

Most Read lists are compiled every quarter.

On the Cover

New Issue Alert

Free Trial Issue

Journal Ranking

Journal Access

Full-text articles are available from 1995 to the present. Access to abstracts is complimentary. Access to full text is limited to print subscribers. Register or login to:

Buy a Subscription Now

Activate Online Access

Publishing Information

Leukemia Research is published by Elsevier.

Access this journal onSciVerse ScienceDirect

About Leukemia Research

Leukemia Research an international journal which brings comprehensive and current information to all health care professionals involved in basic and (or) applied clinical research in leukemias, lymphomas, multiple myeloma and other hematologic malignancies. The editors encourage the submission of articles relevant to normal and leukemic hemopoiesis, biochemistry, cell biology, immunology and molecular biology as well as epidemiologic and clinical studies.

Specifically, of major interest will be articles that encompass the application of oncogenes, growth factors, cell markers, cell cycle and differentiation agents, novel therapeutics and clinical trials in both the acute and chronic leukemias as well as the myelodysplastic syndromes. In addition we solicit selected articles on the rapidly increasing specialty of marrow or stem cell reconstitution after high dose therapy with curative attempt in patients with a wide range of neoplasms.

MDS Foundation Information

The MDS Foundation is a multidisciplinary, international organization devoted to the prevention, treatment, and study of the myelodysplastic syndromes. The organization is based upon the premise that international cooperation will accelerate the process leading to the control and cure of these diseases.